hPMC2 is required for recruiting an ERβ coactivator complex to mediate transcriptional upregulation of NQO1 and protection against oxidative DNA damage by tamoxifen

Oncogene

Volumn 27, Issue 49, 2008, Pages 6376-6384

  Sripathy, S P ^a   Chaplin, L J ^a   Gaikwad, N W ^a   Rogan, E G ^b   Montano, M M ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Antioxidative enzymes; Breast cancer; ER dependent transcription; PARP 1; Tamoxifen

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HYDROXYTAMOXIFEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; ONCOPROTEIN; PROTEIN PMC2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TAMOXIFEN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ARTICLE; BREAST EPITHELIUM; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; UPREGULATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; POLY(ADP-RIBOSE) POLYMERASES; RESPONSE ELEMENTS; RETROVIRIDAE; TAMOXIFEN; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSFECTION; UP-REGULATION;

INDICATOR MINOR;

EID: 54549104700     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.235     Document Type: Article

References (37)

1. Bianco NR, Perry G, Smith MA, Templeton DJ, Montano MM. (2003). Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced DNA damage. Mol Endocrinol 17: 1344-1355.
2. Bolton JL, Thatcher GR. (2008). Potential mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol 21: 93-101.
3. Brummelkamp TR, Bernards R, Agami R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553.
4. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R et al. (2006). Catechol estrogen quinones as initiators of breast and other human cancers: Implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta; e-pub ahead of print.
5. Chang EC, Frasor J, Komm B, Katzenellenbogen BS. (2006). Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147: 4831-4842.
6. Fabian C. (2007). Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices-counterpoint. Cancer Epidemiol Biomarkers Prev 16: 2210-2212.
7. Gaikwad NW, Rogan EG, Cavalieri EL. (2007). Evidence from ESIMS for NQO1-catalyzed reduction of estrogen ortho-quinones. Free Rad Biol Med 43: 1289-1298.
8. Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Eden P et al. (2007). Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 13: 1987-1994.
9. Jordan VC. (2007). Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices-point. Cancer Epidemiol Biomarkers Prev 16: 2207-2209.
10. Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK et al. (2006). A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science 312: 1798-1802.
11. Krishnakumar R, Gamble MJ, Frizzell KM, Berrocal JG, Kininis M, Kraus WL. (2008). Reciprocal binding of PARP-1 and histone H1 at promoters specifies transcriptional outcomes. Science 319: 819-821.
12. Li KM, Todorovic R, Devanesan P, Higginbotham S, Kofeler H, Ramanathan R et al. (2004). Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3,4-quinone in vitro and in female ACI rat mammary gland in vivo. Carcinogenesis 25: 289-297.
13. Liehr JG. (2000). Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 21: 40-54.
14. Lis JT, Kraus WL. (2006). Promoter cleavage: a topoIIbeta and PARP-1 collaboration. Cell 125: 1225-1227.
15. Matthews J, Gustafsson JA. (2003). Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 3: 281-292.
16. Matthews J, Wihlen B, Tujague M, Wan J, Strom A, Gustafsson JA. (2006). Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol 20: 534-543.
17. Menzel HJ, Sarmanova J, Soucek P, Berberich R, Grunewald K, Haun M et al. (2004). Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer 90: 1989-1994.
18. Montano MM, Chaplin L, Deng H, Mesia-Vela S, Gaikwad N, Zahid M et al. (2007). Protective roles of quinone reductase and antiestrogens in estrogen-induced mammary cell tumorigenesis. Oncogene 26: 3587-3590.
19. Montano MM, Deng H, Liu M, Sun X, Singal R. (2004). Transcriptional regulation by the estrogen receptor of antioxidative stress enzymes and its functional implications. Oncogene 23: 2442-2453.
20. Montano MM, Jaiswal AK, Katzenellenbogen BS. (1998). Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-alpha and estrogen receptor-beta. J Biol Chem 273: 25443-25449.
21. Montano MM, Wittmann BM, Bianco NR. (2000). Identification and characterization of a novel factor that regulates quinone reductase gene transcriptional activity. J Biol Chem 275: 34306-34313.
22. Oestergaard MZ, Tyrer J, Cebrian A, Shah M, Dunning AM, Ponder BA et al. (2006). Interactions between genes involved in the antioxidant defence system and breast cancer risk. Br J Cancer 95: 525-531.
23. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ et al. (1997). Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277: 1508-1510.
24. Pavri R, Lewis B, Kim TK, Dilworth FJ, Erdjument-Bromage H, Tempst P et al. (2005). PARP-1 determines specificity in a retinoid signaling pathway via direct modulation of mediator. Mol Cell 18: 83-96.
25. Pettersson K, Grandien K, Kuiper GG, Gustafsson JA. (1997). Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha. Mol Endocrinol 11: 1486-1496.
26. Prestera T, Talalay P. (1995). Electrophile and antioxidant regulation of enzymes that detoxify carcinogens. Proc Natl Acad Sci USA 92: 8965-8969.
27. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P et al. (2001). Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 98: 3410-3415.
28. Routledge EJ, White R, Parker MG, Sumpter JP. (2000). Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER)alpha and ER beta. J Biol Chem 275: 35986-35993.
29. Rushmore TH, Morton MR, Pickett CB. (1991). The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem 266: 11632-11639.
30. Sakoda LC, Blackston CR, Xue K, Doherty JA, Ray RM, Lin MG et al. (2007). Glutathione S-transferase M1 and P1 polymorphisms and risk of breast cancer and fibrocystic breast conditions in Chinese women. Breast Cancer Res Treat.
31. Shang Y, Brown M. (2002). Molecular determinants for the tissue specificity of SERMs. Science 295: 2465-2468.
32. Speirs V, Walker RA. (2007). New perspectives into the biological and clinical relevance of oestrogen receptors in the human breast. J Pathol 211: 499-506.
33. Strange RC, Spiteri MA, Ramachandran S, Fryer AA. (2001). Glutathione-S-transferase family of enzymes. Mutat Res 482: 21-26.
34. Tew KD. (1994). Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54: 4313-4320.
35. Udler M, Maia AT, Cebrian A, Brown C, Greenberg D, Shah M et al. (2007). Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J Clin Oncol 25: 3015-3023.
36. Venugopal R, Jaiswal AK. (1996). Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci USA 93: 14960-14965.
37. Wong CW, Komm B, Cheskis BJ. (2001). Structure-function evaluation of ER alpha and beta interplay with SRC family coactivators. ER selective ligands. Biochemistry 40: 6756-6765.